converting between glp 1 agonists Switching GLP‐1 receptor in clinical practice: Expert consensus and practical guidance Approaches for half-life extension of

The study assessed whether GLP-1 receptor agonists, a class of medicines widely used to treat type 2 diabetes (T2DM) and obesity, were associated with long-term breast cancer outcomes

Ruth Oratz, Medical Oncologist, and Barrie Weinstein, Endocrinologist, on Thursday, February 13th as Sharsheret hosts a timely and important conversation on breast cancer and GLP-1 drugs

Importantly, as shown in a subset of patients, no significant cross-reaction was observed between anti-exenatide antibodies and human GLP-1 or glucagon

In patients with IIH, abrupt cessation of GLP-1RA therapy has been reported to lead to a return of symptoms or new onset IIH in two separate case reports, highlighting the requirement of continuous therapy (22,24)

Real-world studies have shown heterogeneous findings

One step closer to solving the mystery of the anti-inflammatory effects of glucagon-like peptide-1 receptor agonists